According to CNBC's Bob Pisani, all the companies reporting today were beat by a larger amount than anticipated. Pisani looks at the day's market action. » Read More
U.S. sovereign bonds built on this week's gains Wednesday as demand waned for safe haven assets prompted by the Brexit vote.
The Abbott Park, Illinois- based company said it had profit of 41 cents per share. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 53 cents per share. Nine analysts surveyed by Zacks expected $5.26 billion.
U.S. stock-index futures rose on Wednesday as investors cheered better-than-expected earnings from Morgan Stanley.
Ohio Gov. John Kasich inherited a state with a dismal economy. Here's what he says the United States can learn from Ohio's big turnaround.
Jim Cramer rattles off his take on caller favorite stocks, including this popular play on technology.
What's the outcome for currencies if the United Kingdom votes to leave the EU? Michael Binger, Gradient Investments, likes Abbott and Under Armour stocks.
Michael Farr, Farr Miller & Washington, and Kevin Norris, Univest Wealth Management President, discuss their summer market outlooks and give their picks.
The “Halftime Report” experts discuss.
The FMHR traders, and John Spallanzani, GFI Group, debate the trade on pharma stocks after CNBC's Jim Cramer suggests there are positive signs for the sector.
CNBC's David Faber reports on diagnostic test maker Alere saying it rejected Abbott's attempt to terminate a deal.
Most companies are feeling all right about their business, but weak sales growth is making M&A synergies attractive, Roger Altman says.
Some of the names on the move ahead of the open.
Diagnostic test maker Alere said it has rejected a request by Abbott Laboratories to terminate the $5.8 billion deal to buy Alere for a breakup fee.
Jim Cramer sees signs everywhere that the worst is over for pharma.
Discussing the M&A space for biotech and health care with Les Funtleyder, Asset Management Portfolio Manager at ESquared, and Michael Yee, BioTech Analyst at RBC Capital Markets
Abbott Labs said it agreed to St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
CNBC contributor and Former Medtronic CEO Bill George reacts to the merger between St. Jude Medical and Abbott Labs.
Abbott Labs Chairman and CEO Miles White, explains the timing behind the merger with St. Jude Medical.
Abbott Labs Chairman and CEO Miles White discusses whether the company looked at inversion, after announcing a deal to buy St. Jude Medical.
Abbott Labs is buying St. Jude Medical for $25 billion. Abbott Labs Chairman and CEO Miles White, discusses the fit for both companies.